Aditxt, Inc. Proceeds from Issuance of Private Placement
Aditxt, Inc. (ADTX) reported Proceeds from Issuance of Private Placement of $5.50 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-05-15
- Aditxt, Inc. proceeds from issuance of private placement for the quarter ending 2024-06-30 was $4.90M.
- Aditxt, Inc. proceeds from issuance of private placement for the quarter ending 2024-03-31 was $600.00K.
- Aditxt, Inc. proceeds from issuance of private placement for fiscal 2023 was $5.50M.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 1 month | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 3 month as first filed | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $5.50M 10-Q · filed 2024-08-19 | ||||
| 2024-05-31 | $4.20M 10-Q · filed 2024-08-19 | |||||
| 2024-05-02 | $4.20M 10-Q · filed 2024-11-18 | |||||
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-15 | $5.50M 10-Q · filed 2024-05-20 | ||||
| 2023-12-31 | $5.50M 10-K · filed 2024-04-16 | |||||
| 2023-12-29 | $5.40M 10-K · filed 2025-03-31 | |||||
| 2023-08-31 | $9.00M 10-K · filed 2025-03-31 | $9.00M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |